Notably, several inhibitors for CXCR4 have been conceptualized and developed, with AMD3100 standing out as one of the most significant achievements, having been approved by the FDA in 2008 and showing efficacy in the treatment of cancer and AIDS, as well as transplantation (De Clercq, 2019). Here, CXCR4 is linked to cancer.